RLAY Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.32%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,608,841.14

Relay Therapeutics Insider Trading History Chart

Relay Therapeutics Share Price & Price History

^$4.27

▲ +0.11 (2.64%)

As of 12/23/2024 01:46 PM ET

Days: 30 | 90 | 365

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

Relay Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2024	Sanjiv Patel	CEO	Sell	100,000	$5.00	$500,000.00	574,548
10/28/2024	Peter Rahmer	Insider	Sell	1,621	$6.06	$9,823.26	390,063
10/28/2024	Thomas Catinazzo	CFO	Sell	6,802	$6.06	$41,220.12	306,391
7/31/2024	Peter Rahmer	Insider	Sell	13,708	$8.19	$112,268.52	391,929
7/29/2024	Peter Rahmer	Insider	Sell	13,523	$8.54	$115,486.42	420,765
7/29/2024	Thomas Catinazzo	CFO	Sell	10,780	$8.56	$92,276.80	319,650
7/26/2024	Sanjiv Patel	CEO	Sell	36,706	$9.07	$332,923.42	766,130
6/27/2024	Donald A. Bergstrom	Insider	Sell	648	$6.26	$4,056.48	526,779
6/27/2024	Thomas Catinazzo	CFO	Sell	9,373	$6.24	$58,487.52	330,430
6/5/2024	Peter Rahmer	Insider	Sell	20,450	$7.06	$144,377.00	432,425
6/3/2024	Peter Rahmer	Insider	Sell	19,864	$6.47	$128,520.08	493,470
4/29/2024	Peter Rahmer	Insider	Sell	1,345	$6.38	$8,581.10	513,334
4/29/2024	Thomas Catinazzo	CFO	Sell	1,695	$6.38	$10,814.10	339,803
3/27/2024	Donald A. Bergstrom	Insider	Sell	765	$7.70	$5,890.50	530,113
3/27/2024	Thomas Catinazzo	CFO	Sell	348	$7.70	$2,679.60	341,498
1/29/2024	Peter Rahmer	Insider	Sell	1,651	$9.64	$15,915.64	514,977
1/29/2024	Thomas Catinazzo	CFO	Sell	2,005	$9.64	$19,328.20	341,846
12/27/2023	Peter Rahmer	Insider	Sell	244	$11.51	$2,808.44	316,628
12/27/2023	Thomas Catinazzo	CFO	Sell	294	$11.51	$3,383.94	143,851
10/30/2023	Peter Rahmer	Insider	Sell	1,354	$6.03	$8,164.62	316,872
10/30/2023	Thomas Catinazzo	CFO	Sell	1,697	$6.03	$10,232.91	144,145
9/27/2023	Donald A. Bergstrom	Insider	Sell	648	$8.38	$5,430.24	238,484
9/27/2023	Thomas Catinazzo	CFO	Sell	294	$8.38	$2,463.72	145,842
7/28/2023	Peter Rahmer	Insider	Sell	1,352	$11.80	$15,953.60	316,808
7/28/2023	Thomas Catinazzo	CFO	Sell	1,693	$11.80	$19,977.40	146,136
6/27/2023	Donald A. Bergstrom	Insider	Sell	647	$12.12	$7,841.64	240,587
6/27/2023	Thomas Catinazzo	CFO	Sell	294	$12.12	$3,563.28	147,829
4/28/2023	Peter Rahmer	Insider	Sell	739	$11.16	$8,247.24	157,504
4/28/2023	Thomas Catinazzo	CFO	Sell	863	$11.16	$9,631.08	149,272
3/27/2023	Peter Rahmer	Insider	Sell	297	$15.36	$4,561.92	158,243
3/27/2023	Thomas Catinazzo	CFO	Sell	347	$15.36	$5,329.92	150,135
2/8/2023	Sanjiv Patel	CEO	Sell	14,000	$20.98	$293,720.00
1/30/2023	Peter Rahmer	Insider	Sell	740	$21.56	$15,954.40	158,540
1/30/2023	Thomas Catinazzo	CFO	Sell	864	$21.56	$18,627.84	150,482
1/18/2023	Sanjiv Patel	CEO	Sell	28,000	$20.87	$584,360.00	254,554
1/12/2023	Brian Adams	Insider	Sell	9,994	$20.00	$199,880.00	51,531
12/27/2022	Donald A. Bergstrom	Insider	Sell	980	$14.49	$14,200.20	85,886
12/27/2022	Thomas Catinazzo	CFO	Sell	445	$14.49	$6,448.05	50,231
11/10/2022	Sanjiv Patel	CEO	Sell	28,000	$20.00	$560,000.00	254,554
11/8/2022	Sanjiv Patel	CEO	Sell	14,000	$20.18	$282,520.00	254,554
11/1/2022	Donald A. Bergstrom	Insider	Sell	8,000	$22.75	$182,000.00	86,866
10/28/2022	Andy Porter	Insider	Sell	448	$21.54	$9,649.92	45,164
10/28/2022	Thomas Catinazzo	CFO	Sell	1,099	$21.54	$23,672.46	50,676
10/12/2022	Sanjiv Patel	CEO	Sell	14,000	$21.18	$296,520.00	254,554
10/3/2022	Donald A. Bergstrom	Insider	Sell	8,000	$22.43	$179,440.00	88,683
9/27/2022	Brian Adams	Insider	Sell	294	$22.73	$6,682.62	62,548
9/27/2022	Thomas Catinazzo	CFO	Sell	443	$22.73	$10,069.39	51,775
9/14/2022	Sanjiv Patel	CEO	Sell	14,000	$23.47	$328,580.00	254,554
9/8/2022	Mark Murcko	Director	Sell	25,000	$29.95	$748,750.00	996,952
9/8/2022	Thomas Catinazzo	CFO	Sell	26,257	$30.00	$787,710.00	52,218
8/24/2022	Donald A. Bergstrom	Insider	Sell	15,000	$25.00	$375,000.00	89,659
8/5/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	89,659
7/28/2022	Andy Porter	Insider	Sell	452	$21.27	$9,614.04	45,871
7/28/2022	Thomas Catinazzo	CFO	Sell	734	$21.26	$15,604.84	52,218
7/6/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	91,494
6/27/2022	Andy Porter	Insider	Sell	265	$20.31	$5,382.15	46,323
6/27/2022	Thomas Catinazzo	CFO	Sell	300	$20.31	$6,093.00	52,952
6/24/2022	Donald A. Bergstrom	Insider	Sell	8,000	$20.00	$160,000.00	92,493
5/2/2022	Donald A. Bergstrom	Insider	Sell	13,000	$24.62	$320,060.00	92,493
4/28/2022	Donald A. Bergstrom	Insider	Sell	1,811	$25.57	$46,307.27	92,493
4/28/2022	Thomas Catinazzo	CFO	Sell	725	$25.57	$18,538.25	53,252
4/13/2022	Sanjiv Patel	CEO	Sell	28,000	$31.95	$894,600.00	253,740
4/1/2022	Donald A. Bergstrom	Insider	Sell	18,000	$30.32	$545,760.00	94,304
3/29/2022	Andy Porter	Insider	Sell	294	$29.87	$8,781.78
3/29/2022	Thomas Catinazzo	CFO	Sell	282	$29.87	$8,423.34
3/24/2022	Donald A. Bergstrom	Insider	Sell	10,000	$30.00	$300,000.00
3/24/2022	Thomas Catinazzo	CFO	Sell	13,286	$30.00	$398,580.00
3/10/2022	Donald A. Bergstrom	Insider	Sell	10,000	$25.00	$250,000.00
3/1/2022	Donald A. Bergstrom	Insider	Sell	8,000	$23.88	$191,040.00
2/22/2022	Donald A. Bergstrom	Insider	Sell	22,994	$20.94	$481,494.36
12/27/2021	Andy Porter	Insider	Sell	260	$33.10	$8,606.00
12/27/2021	Thomas Catinazzo	SVP	Sell	295	$33.10	$9,764.50

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

From Weiss Ratings | Ad

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

SEC Filings (Institutional Ownership Changes) for Relay Therapeutics (NASDAQ:RLAY)

96.98% of Relay Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Relay Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/13/2024	Exome Asset Management LLC	414,629	$2.94M	2.0%	N/A	0.248%
11/27/2024	Franklin Resources Inc.	1,396,842	$9.43M	0.0%	+3,883.8%	0.835%
11/20/2024	Virtu Financial LLC	47,010	$0.33M	0.0%	N/A	0.028%
11/19/2024	Barclays PLC	251,819	$1.78M	0.0%	+118.4%	0.150%
11/16/2024	Geode Capital Management LLC	2,732,270	$19.35M	0.0%	+15.5%	2.041%
11/15/2024	Barclays PLC	251,819	$1.78M	0.0%	+118.4%	0.188%
11/15/2024	Y Intercept Hong Kong Ltd	51,856	$0.37M	0.0%	N/A	0.039%
11/15/2024	XTX Topco Ltd	47,271	$0.34M	0.0%	+27.9%	0.035%
11/15/2024	Jane Street Group LLC	185,329	$1.31M	0.0%	-6.6%	0.138%
11/15/2024	State Street Corp	4,300,216	$30.45M	0.0%	+1.2%	3.212%
11/15/2024	Quarry LP	36,000	$0.26M	0.1%	N/A	0.027%
11/15/2024	Point72 DIFC Ltd	18,891	$0.13M	0.0%	N/A	0.014%
11/15/2024	Point72 Asset Management L.P.	1,349,400	$9.55M	0.0%	N/A	1.008%
11/15/2024	Maven Securities LTD	337,426	$2.39M	0.0%	N/A	0.252%
11/15/2024	Ikarian Capital LLC	693,350	$4.91M	0.7%	N/A	0.518%
11/15/2024	HighTower Advisors LLC	154,920	$1.10M	0.0%	-48.9%	0.116%
11/15/2024	Point72 Asia Singapore Pte. Ltd.	8,894	$63K	0.0%	N/A	0.007%
11/15/2024	Erste Asset Management GmbH	23,100	$0.17M	0.0%	N/A	0.017%
11/14/2024	Bellevue Group AG	7,377,184	$52.23M	0.8%	+15.7%	5.510%
11/14/2024	Portland Investment Counsel Inc.	10,000	$71K	0.0%	N/A	0.007%
11/14/2024	PDT Partners LLC	127,272	$0.90M	0.1%	-43.8%	0.095%
11/14/2024	Braidwell LP	3,499,427	$24.78M	0.7%	+16.4%	2.614%
11/14/2024	Eventide Asset Management LLC	2,682,083	$18.99M	0.3%	N/A	2.003%
11/14/2024	Verition Fund Management LLC	76,139	$0.54M	0.0%	+451.0%	0.057%
11/14/2024	Sio Capital Management LLC	945,839	$6.70M	2.7%	N/A	0.706%
11/14/2024	Walleye Capital LLC	1,819,983	$12.89M	0.0%	+6,659.2%	1.359%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	223,289	$1.58M	0.0%	+6.5%	0.167%
11/14/2024	Ally Bridge Group NY LLC	626,058	$4.43M	2.4%	N/A	0.468%
11/13/2024	Finepoint Capital LP	1,626,146	$11.51M	0.8%	+1.3%	1.215%
11/13/2024	FMR LLC	89,772	$0.64M	0.0%	+27.4%	0.067%
11/12/2024	Algert Global LLC	513,277	$3.63M	0.1%	+7.6%	0.383%
11/12/2024	Valence8 US LP	26,200	$0.19M	0.1%	N/A	0.020%
11/12/2024	Charles Schwab Investment Management Inc.	1,035,789	$7.33M	0.0%	+26.1%	0.774%
11/9/2024	Intech Investment Management LLC	36,176	$0.26M	0.0%	N/A	0.027%
11/7/2024	First Turn Management LLC	1,226,354	$8.68M	1.4%	N/A	0.916%
11/7/2024	Thrivent Financial for Lutherans	160,458	$1.14M	0.0%	+33.7%	0.120%
11/6/2024	Cornercap Investment Counsel Inc.	10,811	$77K	0.0%	-52.7%	0.008%
11/5/2024	Victory Capital Management Inc.	73,886	$0.52M	0.0%	-3.5%	0.055%
11/5/2024	GSA Capital Partners LLP	15,407	$0.11M	0.0%	-84.3%	0.012%
11/5/2024	Entropy Technologies LP	12,202	$86K	0.0%	-46.5%	0.009%
11/4/2024	Los Angeles Capital Management LLC	31,890	$0.23M	0.0%	-70.0%	0.024%
11/2/2024	Mesirow Financial Investment Management Inc.	14,536	$0.10M	0.0%	-17.7%	0.011%
10/25/2024	China Universal Asset Management Co. Ltd.	25,751	$0.18M	0.0%	+65.1%	0.019%
10/23/2024	Values First Advisors Inc.	10,579	$75K	0.0%	N/A	0.008%
10/19/2024	Allspring Global Investments Holdings LLC	41,203	$0.29M	0.0%	+6.6%	0.031%
10/10/2024	Exchange Traded Concepts LLC	20,649	$0.15M	0.0%	-22.4%	0.015%
10/3/2024	SG Americas Securities LLC	55,084	$0.39M	0.0%	N/A	0.041%
8/16/2024	Algert Global LLC	476,888	$3.11M	0.1%	+57.9%	0.356%
8/16/2024	Driehaus Capital Management LLC	616,220	$4.02M	0.0%	+54.9%	0.460%
8/15/2024	Susquehanna Fundamental Investments LLC	53,442	$0.35M	0.0%	+248.7%	0.040%
8/15/2024	The Manufacturers Life Insurance Company	215,588	$1.41M	0.0%	-8.3%	0.161%
8/15/2024	Millennium Management LLC	1,149,177	$7.49M	0.0%	+404.2%	0.858%
8/15/2024	Deerfield Management Company L.P. Series C	46,702	$0.30M	0.0%	N/A	0.035%
8/15/2024	AQR Capital Management LLC	67,243	$0.44M	0.0%	+362.2%	0.050%
8/15/2024	Caxton Associates LP	107,568	$0.70M	0.0%	-17.8%	0.080%
8/14/2024	Squarepoint Ops LLC	144,986	$0.95M	0.0%	N/A	0.108%
8/14/2024	Marshall Wace LLP	276,702	$1.80M	0.0%	N/A	0.207%
8/14/2024	Logos Global Management LP	1,300,000	$8.48M	0.7%	N/A	0.979%
8/14/2024	Integral Health Asset Management LLC	750,000	$4.89M	0.5%	+3.4%	0.560%
8/14/2024	EverSource Wealth Advisors LLC	5,750	$37K	0.0%	N/A	0.004%
8/14/2024	ProShare Advisors LLC	20,883	$0.14M	0.0%	-20.3%	0.016%
8/14/2024	Profund Advisors LLC	36,418	$0.24M	0.0%	-49.7%	0.027%
8/13/2024	Ensign Peak Advisors Inc	55,450	$0.36M	0.0%	+24.3%	0.042%
8/13/2024	Thrivent Financial for Lutherans	120,011	$0.78M	0.0%	N/A	0.090%
8/12/2024	Hsbc Holdings PLC	41,339	$0.26M	0.0%	+118.3%	0.031%
8/12/2024	E Fund Management Co. Ltd.	11,778	$77K	0.0%	-46.3%	0.009%
8/9/2024	Renaissance Technologies LLC	909,037	$5.93M	0.0%	+19.1%	0.685%
8/9/2024	Dimensional Fund Advisors LP	1,520,340	$9.91M	0.0%	-5.0%	1.145%
8/8/2024	Federated Hermes Inc.	312,444	$2.04M	0.0%	-7.1%	0.235%
8/8/2024	DekaBank Deutsche Girozentrale	60,000	$0.39M	0.0%	-13.0%	0.045%
8/8/2024	American Century Companies Inc.	178,088	$1.16M	0.0%	+19.4%	0.134%
8/6/2024	Los Angeles Capital Management LLC	106,169	$0.69M	0.0%	+661.7%	0.080%
8/6/2024	Candriam S.C.A.	703,429	$4.59M	0.0%	+38.4%	0.530%
8/5/2024	Victory Capital Management Inc.	76,539	$0.50M	0.0%	+11.2%	0.058%
8/3/2024	TD Asset Management Inc	206,056	$1.34M	0.0%	-42.5%	0.155%
8/1/2024	Rhumbline Advisers	163,895	$1.07M	0.0%	+4.8%	0.123%
7/29/2024	Principal Financial Group Inc.	14,580	$95K	0.0%	-43.4%	0.011%
7/26/2024	Allspring Global Investments Holdings LLC	38,656	$0.25M	0.0%	+304.0%	0.029%
7/26/2024	Bank of New York Mellon Corp	354,667	$2.31M	0.0%	+15.7%	0.267%
7/25/2024	Baillie Gifford & Co.	284,058	$1.85M	0.0%	-19.6%	0.214%
5/20/2024	Virtu Financial LLC	10,461	$87K	0.0%	N/A	0.008%
5/16/2024	Jacobs Levy Equity Management Inc.	1,675,403	$13.91M	0.1%	-0.5%	1.262%
5/16/2024	Bayesian Capital Management LP	38,600	$0.32M	0.0%	N/A	0.029%
5/16/2024	Caxton Associates LP	130,816	$1.09M	0.1%	-53.1%	0.099%
5/15/2024	Public Employees Retirement System of Ohio	94,341	$0.78M	0.0%	-4.1%	0.071%
5/15/2024	Bellevue Group AG	5,926,618	$49.19M	0.8%	-0.2%	4.465%
5/15/2024	Price T Rowe Associates Inc. MD	6,879,597	$57.10M	0.0%	-19.8%	5.183%
5/14/2024	American International Group Inc.	46,686	$0.39M	0.0%	+4.0%	0.035%
5/10/2024	Vanguard Group Inc.	11,815,669	$98.07M	0.0%	+10.9%	8.901%
5/8/2024	ProShare Advisors LLC	26,214	$0.22M	0.0%	+14.9%	0.020%
5/8/2024	Russell Investments Group Ltd.	179,972	$1.49M	0.0%	+57.2%	0.136%
5/7/2024	Susquehanna Fundamental Investments LLC	15,325	$0.13M	0.0%	N/A	0.012%
5/7/2024	Susquehanna Portfolio Strategies LLC	208,356	$1.73M	0.0%	-0.8%	0.157%
5/7/2024	Swiss National Bank	163,500	$1.36M	0.0%	+4.5%	0.123%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	54,917	$0.46M	0.0%	+7.2%	0.041%
5/1/2024	Baillie Gifford & Co.	353,226	$2.93M	0.0%	-5.5%	0.267%
4/30/2024	Allspring Global Investments Holdings LLC	9,569	$79K	0.0%	N/A	0.007%
4/29/2024	Principal Financial Group Inc.	25,775	$0.21M	0.0%	-6.8%	0.019%
4/29/2024	China Universal Asset Management Co. Ltd.	25,210	$0.21M	0.0%	+76.8%	0.019%
4/26/2024	Mesirow Financial Investment Management Inc.	17,627	$0.15M	0.0%	N/A	0.013%

Data available starting January 2016

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $4.27

$4.12

$4.27

50 Day Range

MA: $5.38

$4.16

$6.80

52 Week Range

Now: $4.27

$4.11

$12.14

Volume

754,719 shs

Average Volume

1,565,167 shs

Market Capitalization

$714.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Who are the company insiders with the largest holdings of Relay Therapeutics?: Relay Therapeutics' top insider shareholders include:
Sanjiv Patel (CEO)
Donald A Bergstrom (Insider)
Peter Rahmer (Insider)
Thomas Catinazzo (CFO)
Brian Adams (Insider)
Learn More about top insider investors at Relay Therapeutics.
Who are the major institutional investors of Relay Therapeutics?: Relay Therapeutics' top institutional shareholders include:
Bellevue Group AG — 5.51%
State Street Corp — 3.21%
Braidwell LP — 2.61%
Geode Capital Management LLC — 2.04%
Eventide Asset Management LLC — 2.00%
Walleye Capital LLC — 1.36%
Learn More about top institutional investors of Relay Therapeutics stock.
Which institutional investors are selling Relay Therapeutics stock?: Within the last quarter, RLAY stock was sold by these institutional investors:
HighTower Advisors LLC
PDT Partners LLC
GSA Capital Partners LLP
Los Angeles Capital Management LLC
Jane Street Group LLC
Cornercap Investment Counsel Inc.
Entropy Technologies LP
Exchange Traded Concepts LLC
During the previous year, company insiders that have sold Relay Therapeutics company stock include:
Sanjiv Patel (CEO)
Donald A Bergstrom (Insider)
Peter Rahmer (Insider)
Thomas Catinazzo (CFO)
Learn More investors selling Relay Therapeutics stock.
Which institutional investors are buying Relay Therapeutics stock?: Within the last quarter, RLAY stock was bought by institutional investors including:
Eventide Asset Management LLC
Walleye Capital LLC
Franklin Resources Inc.
Point72 Asset Management L.P.
First Turn Management LLC
Bellevue Group AG
Sio Capital Management LLC
Ikarian Capital LLC